Pharma Package lands — Divisive reaction — AMR market reward

Peter Bogaert's commentary appeared in a Financial Times article about the European Commission's proposal to revise the European Union's pharmaceutical legislation--the first overhaul of pharmaceutical legislation in 20 years.  As part of the legislation, the European Commission is advancing a plan to cut the number of years of market exclusivity — the period before a drugmaker faces competition from generic manufacturers — from 10 to eight years

According to Peter, the exclusivity reforms were unlikely to increase innovation. “The incentive value of the exclusivities mainly matters at the time when a company decides what clinical development programmes to invest in,” he said.

Click here to read the full article.